What is Denali Therapeutics Inc (DNLI) stock price today?

Denali Therapeutics Inc (DNLI) currently trades at $18.60 per share. The stock has a market capitalization of $2.95B and a P/E ratio of —x.

Is DNLI stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Denali Therapeutics Inc has a Smart Value Score of 25/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is —/9 and Altman Z-Score is —.

DNLI

Denali Therapeutics Inc

NASDAQ: DNLI · HEALTHCARE · BIOTECHNOLOGY

$18.60

-7.28% today

Updated 2026-04-29

Market cap

$2.95B

P/E ratio

—

P/S ratio

3,643.65x

EPS (TTM)

$-2.97

Dividend yield

—

52W range

$13 – $24

Volume

1.7M

Market cap

$2.95B

P/E ratio

—

P/S ratio

3,643.65x

EPS (TTM)

$-2.97

Dividend yield

—

52W range

$13 – $24

Volume

1.7M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

3.7

Growth

5.0

Quality

C+

3.0

Profitability

5.0

Valuation

C+

—/9

Piotroski F-Score

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →200 stocks currently score above 75

Price targets

Analyst target

$35.64

+91.61%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

1 Strong Buy17 Buy1 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

Insufficient data

Risks

- Thin margins at 0.00%

- Negative free cash flow $-100.06M

- Revenue declining -100.00% QoQ

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$108.46M	$330.53M	$0.00	$0.00	$0.00
Net income	$-325.99M	$-145.22M	$-422.77M	$-512.54M	$-128.55M
EPS	—	—	—	—	$-2.97
Free cash flow	$-262.55M	$-370.93M	$-363.61M	$-422.10M	$-100.06M
Profit margin	-300.56%	-43.94%	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
DNLI	$2.95B	25	3.7	3.0	5.0	5.0	—	Avoid
LLY	$789.69B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.64B	59	4.7	9.0	3.3	6.0	-41.97%	Buy
ABBV	$351.47B	63	4.0	8.0	4.7	5.0	-24.92%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Denali Therapeutics Inc trades at $18.60. Our Smart Value Score of 25/100 indicates the stock is weak.

Frequently asked questions

What is Denali Therapeutics Inc's stock price?

Denali Therapeutics Inc (DNLI) trades at $18.60.

Is Denali Therapeutics Inc overvalued?

Smart Value Score 25/100 (Grade F, Strong Sell).

What is the price target of Denali Therapeutics Inc (DNLI)?

The analyst target price is $35.64, representing +91.6% upside from the current price of $18.60.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio3,643.65x

ROE-45.70%

Beta1.10

50D MA$20.26

200D MA$17.40

Shares out0.16B

Float0.14B

Short ratio—

Avg volume1.7M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

DNLI vs LLY →DNLI vs JNJ →DNLI vs ABBV →Stock screener →